Please provide your email address to receive an email when new articles are posted on . Second-line lisocabtagene maraleucel more than quadrupled EFS compared with standard therapy for patients with ...
Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.
Please provide your email address to receive an email when new articles are posted on . Patients assigned liso-cel achieved longer median PFS and OS compared with standard of care. ORR was ...
Liso-cel therapy significantly improves response rates and survival outcomes in relapsed/refractory CLL/SLL patients compared to standard-of-care treatments. The TRANSCEND CLL 004 trial showed a 52.5% ...
Hosted on MSN
CAR T-Cell Therapy, Liso-Cel, Achieves Superior Outcomes For Patients With Hard-To-Treat Large B-Cell Lymphoma
Facing a diagnosis of large B-cell lymphoma that has relapsed or hasn’t responded to initial treatments can feel overwhelming. However, recent advancements in treatments — such as an approach known as ...
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) today announced that data from the TRANSCEND CLL 004 and TRANSCEND NHL 001 trials studying the investigational anti-CD19 chimeric ...
A manufacturing shortfall likely cost Bristol Myers Squibb the chance of an FDA approval for CAR-T therapy liso-cel by the end of 2020—and sent a potential $9-apiece Celgene deal sweetener into the ...
Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study. Preliminary safety and efficacy data of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback